Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Tolaney

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
ESMO Open|October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancerS Morganti, R J Kusmick, M E Hughes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE studyH S Rugo, J O'Shaughnessy, F Boyle, et al.
ESMO Open|July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational studyC Corti, X Chu, P Exman, et al.
ESMO Open|November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open|August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapyA Strahan, Q Jin, A S Raghavendra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2023
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialL M Spring, S M Tolaney, G Fell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]M P Goetz, M Toi, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.
ESMO Open|January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancersF Lynce, O Martínez-Sáez, B Walbaum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
ESMO Open|October 1, 2025
Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancerS Morganti, R J Kusmick, M E Hughes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 26, 2022
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE studyH S Rugo, J O'Shaughnessy, F Boyle, et al.
ESMO Open|July 27, 2025
Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational studyC Corti, X Chu, P Exman, et al.
ESMO Open|November 5, 2024
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆A S Raghavendra, D B Zakon, Q Jin, et al.
ESMO Open|August 29, 2025
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapyA Strahan, Q Jin, A S Raghavendra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2023
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialL M Spring, S M Tolaney, G Fell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2025
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727]M P Goetz, M Toi, J Huober, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3M P Goetz, M Toi, J Huober, et al.
ESMO Open|January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancersF Lynce, O Martínez-Sáez, B Walbaum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Overall survival with abemaciclib in early breast cancerS Johnston, M Martin, J O'Shaughnessy, et al.
Pageof 6